MA, Biological Anthropology DSc, Immunology and Infectious Disease.
Dr. Nathan Wolfe is the Lorry I. Lokey Business Wire Consulting Professor in Human Biology at Stanford University. He is the Founder of Metabiota, a company that specializes in microbiological research, products and services, and the Chairman of Global Viral, a non-profit that promotes understanding, exploration and stewardship of the microbial world. Dr. Wolfe received his doctorate in Immunology & Infectious Diseases from Harvard in 1998. He has received numerous awards including a Fulbright fellowship and the NIH Director’s Pioneer Award and was named a National Geographic Emerging Explorer in 2009 and a World Economic Forum Young Global Leader in 2010. Dr. Wolfe has over eight years of experience living and conducting biomedical research in Southeast Asia (Malaysia) and sub-Saharan Africa (Cameroon and Uganda), and he currently coordinates activities of over 50 scientists and staff in countries around the world. He has received support totaling over $60m in grants and contracts from Google.org, the National Institutes of Health, the National Science Foundation, the Bill & Melinda Gates Foundation, the US Department of Defense among others. He has over 80 scientific publications, and his critically acclaimed book, The Viral Storm, has been published in six languages and was shortlisted in 2012 for the Royal Society’s Winton Prize.
Mr. Robert Mann has extensive experience leading and managing operations of top-tier healthcare and medical device companies, as well as implementing approaches to improve the standard of global health care.
As President and CEO of Metabiota Inc., Mr. Mann forwards the company’s mission to mitigate threats from, and create harmony with, the microbial world through the development of international medical diplomacy programs and partnerships between government, military and public health systems, academic institutions, NGOs and health related products for the private sector.
Prior to joining Metabiota Inc., Mr. Mann served as President of Lumenis Americas, the largest medical laser company in the world. During his tenure at Lumenis, Mr. Mann led the global dermatology practice and established a new standard of care for the treatment of traumatic injuries to the skin. Prior to Lumenis, Mr. Mann served as Group Vice President at Laserscope, acquired by American Medical Systems in 2006.
Eddy Rubin joined Metabiota as Chief Science Officer in July 2016 after several decades of running large-scale science programs at the Lawrence Berkeley National Laboratory.
Just prior to joining Metabiota, Dr. Rubin acted as the Director of the DOE Joint Genome Institute (JGI). The JGI is a large genomic facility and was a major participant in the Human Genome Project under his leadership, sequencing 13% of the human genome as well as the genomes of thousands of microbes, viruses and fungi. His research has included a series of pioneering studies in the area of metagenomics, deriving important insights from his investigation of the microbial communities inhabiting a variety of environments. Dr. Rubin has published over 250 peer-reviewed manuscripts with more than 35 of them appearing in the journals Science and Nature. He is a member of the Genome Canada Board of Directors, Chair of the Genomic Institute of Singapore’s Scientific Advisory Board and was a member of the Welcome Trust Sanger Center’s Scientific Advisory Board from 2008-2012. He received an Honorary Doctorate of Science degree from Middlebury College, the University of Rochester Dean’s Award, the Netherlands Heart Association Declaration of Esteem, the American Heart Association Established Investigator Award, and has been inducted into the American Society of Clinical Investigation. He served as a member of the Board of Reviewing Editors for the journal Science from 2001 to 2012.
Dr. Rubin received a BA in Physics at the University of California San Diego, his MD & PhD (Biophysics) at the University of Rochester, and completed his clinical training in Human Genetics at the University of California San Francisco.
Michael Bell joined Metabiota as Chief Financial Officer in January 2016 and brings to the role over 20 years of international finance and accounting experience gained from a wide range of strategic, commercial and operational positions.
Prior to joining Metabiota, Michael served as CFO of Singulex, a clinical diagnostics company, where he led the business through a period of significant growth and strategic transformation. Before this, Michael held executive and leadership positions at Novartis. He served as CFO of Novartis Diagnostics, a global provider of blood screening solutions, and as Finance Head for the Asia Pacific, Middle East & Africa region of Novartis Vaccines, where he worked closely with commercial teams to develop new business in emerging markets. Prior to Chiron Corporation’s acquisition by Novartis, Michael served in Europe as Finance Director for the multinational biotechnology firm. Before joining the healthcare industry, Michael worked for several years in public accounting with both Ernst & Young and Deloitte.
Michael holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England & Wales.
Nalini leads product management and marketing at Metabiota. In this role, she is responsible for building out and launching Metabiota’s product offerings to a global customer base.
Prior to joining Metabiota, Nalini was Senior Vice President Product Management at Risk Management Solutions (RMS) where she led product management for RMS(one), first-in-its class, cloud based risk management platform; as well as RMS' flagship software suites. In this role, she was responsible for driving the multi-year product roadmap, leading product design, user experience, and technical publications for all of RMS’ software products.
Before joining RMS, she held roles in applications engineering and development at Advent, a provider of software solutions for investment management, and TenFold, a provider of application development environments. Nalini holds a BS in chemical engineering from Osmania University, Hyderabad, India, and an MS in chemical engineering from Florida State University.
Htin Hlaing is the Vice President of Engineering at Metabiota with extensive experience in R&D engineering and software integration. In this role, Htin builds and heads world class engineering team delivering Metabiota's product offerings to the global customer base. Htin's a hands-on executive with expertise in agile development, big data infrastructure, internet technologies, cloud services, enterprise software and product design.
Prior to Metabiota, Htin was Vice President of Engineering at SugarSync, a Cloud backup and sync company (acquired by j2 Global). At SugarSync, Htin was responsible for transforming the distributed engineering teams to be highly productive agile teams delivering all of SugarSync's desktop, mobile, web based products and massively distributed backend infrastructure. Prior to SugarSync, Htin held senior management positions at Flurry, Inc (acquired by Yahoo! Inc.) and Attributor Corporation (acquired by Digimarc). Before coming to Attributor, he held engineering management positions in various Silicon Valley startup companies.
He holds Bachelors of Science degree in Computer Science from University of California, Irvine and Masters of Science degree in Software Management from Carnegie Mellon University.
Marissa Dixon has broad Human Resources experience in a range of high-growth, fast-paced industries. Over the last several years, she has specialized in the distinctive needs of the Biotechnology field.
Prior to joining Metabiota, Marissa served as the Director of Human Resources for DuPont Industrial Biosciences supporting the Research & Development team in 4 countries. Marissa has a proven track record of engaging global teams to execute on company initiatives in unique and culturally significant ways.
Marissa holds an M.S. in Human Resource Design and an M.A. in Psychology from Claremont Graduate University as well as an undergraduate degree in Social Sciences from Cal Poly San Luis Obispo.
Jen Bruursema has been on the sharp end of commercializing and marketing some of the most novel approaches to preventing and diagnosing infectious diseases as well as detecting and treating life-threatening genetic conditions. From her first foray into molecular diagnostics at Digene Corporation, later acquired by QIAGEN, she exponentially grew clinical demand for the Digene HPV Test brand that spurred a global multi-billion dollar industry for human papillomavirus DNA testing. She also designed marketing strategy and tactics to position assays for CMV, EBV, West Nile and other infectious agents to the CLIA laboratory customer segment. She further expanded her product portfolio to include next generation sequencing for the detection of Down syndrome as Director of Marketing at Ariosa Diagnostics, now owned by Roche; stem cell therapeutics for regenerative medicine applications such as cerebral palsy and autism as Senior Director of Global Healthcare Communications at Cord Blood Registry, acquired by AMAG Pharmaceuticals; and next generation sequencing for pathogen detection as Head of Marketing at Karius. Jen has underpinned this career expertise working across a broad spectrum of financial and cultural environments, including startups, private equity-backed companies and publicly traded corporations.
Megan Hodge is Metabiota’s Global Head of Business Development, Risk Products. She was previously the Global Managing Director and Branch Manager of Guy Carpenter’s Chicago USA office. In this past role, she closely worked with a number of nationwide and global P&C insurance providers to analyze their business portfolios and understand their strategic objectives, including: optimizing reinsurance solutions (i.e. designing programs that best meet each company’s unique risk and capital management needs) as well as to address their broader needs (i.e. outside of reinsurance, ranging from growth initiatives to product development to incorporating emerging technologies into their current platforms).
Prior to joining Guy Carpenter in 2009, Megan was part of Aon Benfield’s (fka Benfield’s) North American reinsurance intermediary practice. She began her career at Arthur Andersen in its value-based solutions consulting practice, with a focus on insurance recoveries.
Additionally, Megan is an outgoing Board Member and Grants Committee member of Midwest Division - Insurance Industry Charitable Foundation (IICF), a Major Grants Committee member of the Oak Park River Forest Infant Welfare Society, and a member of the Leukemia & Lymphoma Society’s Chicago-based “Just Cure It” team.